[Effect of electroacupuncture on intestinal Toll–like receptor 4 and nuclear factor-kappa B in obese rats]
Objective: To determine the effect of electroacupuncture (EA) on intestinal Toll-like receptor 4 (TLR4) and nuclear factor-kappa B (NF-kB) in obese mice, so as to explore the mechanism of action of acupuncture to lose weight.
Methods: A total of 50 male Wistar rats were randomly divided into control and model of the group. high-fat feed used to establish a mouse model of obesity, and after modeling, 24 rats were randomly divided into model group, TLR4 inhibitor group and EA group, with 8 rats in each group. Mice in group EA by EA at “Guanyuan” (CV4), “Zhongwan” (CV12), “Zusanli” (ST36), and “Fenglong” (ST40), 10 minutes each time, three times a week, and they were in a group of inhibitors TLR4 were given intraperitoneal injection of TAK-242 three times a week; course of treatment was 8 weeks for both groups. weight and the body’s blood sugar was measured every two weeks. Co-immunoprecipitation was used to observe the interaction between TLR4 and NF-kB p65 in colon tissue; electrophoretic mobility shift test is used to measure the activity of NF-kB p65; Western blot was used to measure the expression of TLR4 protein, phosphorylated nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha (p-IκBα), and NF-kB p65; Quantitative real-time PCR was used to measure mRNA expression of TLR4, NF-kB p65 and IκBα.
Results: Compared with the control group, the model group had significant increases in weight, blood glucose, and protein and mRNA expression of TLR4 and NF-kB p65 (P <0.01, P <0.05), as well as a significant increase in interaction between TLR4 and NF-kB p65 and NF-kB p65 activity (P <0.05, P <0.01). Compared with the model group, EA group had a significant reduction in body weight (P <0.05), both groups EA and TLR4 inhibitor group had a significant reduction in blood glucose, and protein and mRNA expression of TLR4, p-IκBα and NF -kB p65 (P <0.05, P <0.01), as well as a significant reduction in the activity of NF-kB p65 (P <0.01).
Conclusion: EA can effectively regulate TLR4 intestine, inhibits the interaction between TLR4 and NF-kB p65, and reduce the activity of NF-kB p65, which may be a potential mechanism of EA in reducing weight and blood glucose in obese mice.
Sex-Differential Impact of Human Cytomegalovirus Infection in vitro reactivity to Tol -As Receptor 2 4 and 7/8 Infant Stimulation in Gambia
Human cytomegalovirus (HCMV) infection rates approaching 100% in the first year of life in low-income countries. It is not known whether the drive is turning into innate immunity early in life and thus altered immune reactivity against infection and vaccine. Given a full arsenal of sex differences in immunity, it is feasible that the immunological effects of HCMV will be different in men and women.
We analyzed ex vivo innate cytokine responses to a panel of pulses like receptor (TLR) ligand in 108 nine-month-old Gambia men and women to participate in vaccine trials. We found evidence that reactivity pressed HCMV TLR2 and TLR7 / 8 arousal in women but not men. This is likely to contribute to sex differences in response to infections and vaccines early in life and have implications for the development of TLR ligand as a vaccine adjuvant. HCMV effective vaccine development will be able to avoid some of the potentially negative effects of HCMV infection in childhood.
TLR4 Peptide |
|||
MBS152670-005mg | MyBiosource | 0.05mg | EUR 175 |
TLR4 Peptide |
|||
MBS152670-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
TLR4 Blocking Peptide |
|||
33R-4969 | Fitzgerald | 100 ug | EUR 119 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TLR4 antibody, catalog no. 70R-9659 |
TLR4 Blocking Peptide |
|||
33R-10686 | Fitzgerald | 50 ug | EUR 145 |
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of TLR4 antibody, catalog no. 70R-11719 |
TLR4 Blocking Peptide |
|||
3253BP-50 | Biovision | each | EUR 183.6 |
TLR4 Blocking Peptide |
|||
AF7017-BP | Affbiotech | 1mg | EUR 234 |
TLR4 Blocking Peptide |
|||
MBS428886-01mg | MyBiosource | 0.1mg | EUR 230 |
TLR4 Blocking Peptide |
|||
MBS9618097-1mg | MyBiosource | 1mg | EUR 380 |
TLR4 Blocking Peptide |
|||
MBS9618097-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
TLR4 Peptide - middle region |
|||
MBS3248533-01mg | MyBiosource | 0.1mg | EUR 180 |
TLR4 Peptide - middle region |
|||
MBS3248533-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
TLR4 Peptide - middle region |
|||
MBS3239101-01mg | MyBiosource | 0.1mg | EUR 180 |
TLR4 Peptide - middle region |
|||
MBS3239101-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
TLR4 Peptide-middle region |
|||
MBS3249570-01mg | MyBiosource | 0.1mg | EUR 180 |
TLR4 Peptide-middle region |
|||
MBS3249570-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
004-04 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
TLR4 Peptide - C-terminal region |
|||
MBS3239146-01mg | MyBiosource | 0.1mg | EUR 180 |
TLR4 Peptide - C-terminal region |
|||
MBS3239146-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
Peptide T |
|||
057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FGL Peptide |
|||
073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
APK peptide |
|||
076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
NEF peptide |
|||
076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
TLR4 Antibody (Center) Blocking Peptide |
|||
MBS9228343-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
TLR4 Antibody Antigenic Blocking Peptide |
|||
MBS544579-025mg | MyBiosource | 0.25mg | EUR 280 |
TLR4 Antibody Antigenic Blocking Peptide |
|||
MBS544579-5x025mg | MyBiosource | 5x0.25mg | EUR 1110 |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
AAP59041-100UG - TLR4 Peptide - middle region |
|||
AAP59041-100UG | Aviva Systems Biology | 100ug | EUR 99 |
Vasonatrin Peptide (VNP) |
|||
005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Phosphate Acceptor Peptide |
|||
058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - FAM Labeled |
|||
FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
FGL Peptide - Cy3 Labeled |
|||
FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
Pedal Peptide (Pep) (Aplysia) |
|||
047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
FGL Peptide - FITC Labeled |
|||
FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
AF-16 Peptide - Antibody |
|||
H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
Schizophrenia Related Peptide |
|||
047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - FAM Labeled |
|||
FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
PGMtide Peptide - Cy3 Labeled |
|||
FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Calmodulin Binding Peptide 1 |
|||
070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
Catch-Relaxing Peptide (CARP) |
|||
047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
FGL Peptide - Rhodamine Labeled |
|||
FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Glycogenolysis-Inhibiting Peptide |
|||
023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Peptide 34 / GPR-54 Agonist |
|||
048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Antimicrobial Trp-rich peptide |
|||
004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Myosin Kinase Inhibiting Peptide |
|||
058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Peptide YY (PYY) (3-36) (Human) |
|||
059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
Peptide YY (PYY) (Human) - Antibody |
|||
H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
PGMtide Peptide - Rhodamine Labeled |
|||
FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Peptide YY (PYY) (Human) - EIA Kit |
|||
EK-059-01 | PHOENIX PEPTIDE | 96 wells | EUR 617.76 |
Peptide YY (PYY) (Human) - RIA Kit |
|||
RK-059-01 | PHOENIX PEPTIDE | 125 tubes | EUR 814.32 |
Kemptide / Phosphate Acceptor Peptide |
|||
058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Bioactive Secretory Peptide Library |
|||
L-009 | PHOENIX PEPTIDE | 1016 peptides | EUR 31350.24 |
PACAP-Related Peptide (PRP) (Rat) |
|||
052-11 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Galanin-Like Peptide (GALP) (Rat) |
|||
026-52 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
T-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Virus Replication Inhibiting Peptide |
|||
070-85 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Crustacean Cardioactive Peptide (CCAP) |
|||
047-24 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Pri Peptide from sORF pri RNA |
|||
069-77 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Alzheimer Fingerprint Peptide Library |
|||
L-011 | PHOENIX PEPTIDE | 85 peptides | EUR 6529.68 |
u PAR (84-95) Scrambled Peptide |
|||
072-47 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
PACAP-Related Peptide (PRP) (Human) |
|||
052-10 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Scrambled Control for Pri Peptide |
|||
069-78 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide (Helix aspersa) |
|||
047-31 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Annexin A1 Binding Peptide, IF7CRR |
|||
025-72 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Galanin-Like Peptide (GALP) (Human) |
|||
026-51 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
027-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
AAP59160-100UG - TLR4 Peptide - C-terminal region |
|||
AAP59160-100UG | Aviva Systems Biology | 100ug | EUR 99 |
Kinetensin / Neurotensin Related Peptide |
|||
048-01 | PHOENIX PEPTIDE | 500 μg | EUR 58.32 |
Small Cardioactive Peptide A (SCPA) |
|||
047-76 | PHOENIX PEPTIDE | 1 mg | EUR 64.8 |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
027-33 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
030-05 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
G-064-07 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Galanin-Like Peptide (GALP) (Porcine) |
|||
026-50 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Human) |
|||
027-07 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
027-40 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
PGMtide Control Peptide - FAM Labeled |
|||
FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Growth Blocking Peptide - FAM Labeled |
|||
FG-046-92A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
PGMtide Control Peptide - Cy3 Labeled |
|||
FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
Chop-Suey / Variety Peptide Library |
|||
L-001 | PHOENIX PEPTIDE | 238 peptides | EUR 7400.16 |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
016-50 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
016-51 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
059-07 | PHOENIX PEPTIDE | 100 μg | EUR 295.92 |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
059-08 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
059-11 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
059-12 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Hypocholesterolemic Peptide / IIAEK (Bovine) |
|||
028-37 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Fractalkine Chemokine Domain peptide (41-52) (Human) |
|||
026-82 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Fractalkine Chemokine Domain peptide (53-60) (Human) |
|||
026-83 | PHOENIX PEPTIDE | 200 μg | EUR 135 |
Fractalkine Chemokine Domain peptide (60-71) (Human) |
|||
026-84 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide ( Lymnae stagnalis) |
|||
047-30 | PHOENIX PEPTIDE | 5 mg | EUR 129.6 |
Peptide F (Bovine) - I-125 Labeled |
|||
T-024-58 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Kappa-Receptor, C-terminal peptide |
|||
002-98 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Angiotensin II - constrained peptide 1 |
|||
004-09 | PHOENIX PEPTIDE | 500 μg | EUR 165.24 |
VEGFR binding peptide KH / QKRKRKKSRKKH |
|||
007-58 | PHOENIX PEPTIDE | 100 μg | EUR 158.76 |
Delta-Sleep-Inducing Peptide (DSIP) |
|||
070-22 | PHOENIX PEPTIDE | 500 μg | EUR 27 |
[Thr5]-Speract / Sperm Activating Peptide |
|||
070-71 | PHOENIX PEPTIDE | 1 mg | EUR 114.48 |
Stresscopin Related Peptide (SRP) (Human) |
|||
019-27 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Gastrin Releasing Peptide (GRP) (Porcine) |
|||
027-13 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
[D-Ala1]-Peptide T - Biotin Labeled |
|||
B-057-02 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
F3 Peptide (4-13) / HMGN2 Fragment 3 (4-13) |
|||
004-13 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
BACKGROUND To study the role of long chain of noncoding RNA (lncRNA) associated metastasis-lung adenocarcinoma transcript 1 (MALAT1), microRNA-503 (miR-503), Toll-like receptor 4 (TLR4) axis signaling in the pathogenesis of pulmonary arterial hypertension (PAH) ,